Patents by Inventor Harald W. Sontheimer
Harald W. Sontheimer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140248291Abstract: Methods, kits, and compositions are provided for addressing cancer through the interaction of bradykinin (BK) and the bradykinin-2-receptor (B2R). This interaction controls cellular invasion, as has been unexpectedly observed in glioma cells, A composition is provided for the treatment of cancer by disrupting this interaction using an inhibitor or BK or B2R that can. be administered to the subject. Diagnostic processes are provided, involving measuring levels of BK or B2R to determine the potential for cancer (or to determine the invasive potential of a given cancer). Modulators of BK. and B2R may be used to modulate cellular migration, both in vivo and in vitro.Type: ApplicationFiled: March 30, 2012Publication date: September 4, 2014Applicant: The UAB Research FoundationInventors: Harald W. Sontheimer, Vedrana Montana Parpura
-
Publication number: 20120183544Abstract: The present invention provides fusion proteins for the detection and treatment of neuroectodermal tumors. Previous work demonstrated that chlorotoxin is specific for glial-derived or meningioma-derived tumor cells. The current invention has extended the use of chlorotoxin-cytotoxin fusion proteins to treat the whole class neuroectodermal tumors such as gliomas, meningiomas, ependymonas, medulloblastomas, neuroblastomas, gangliomas, pheochromocytomas, melanomas, PPNET's, small cell carcinoma of the lung, Ewing's sarcoma, and metastatic tumors in the brain. Also, diagnostic methods are provided for screening neoplastic neuroectodermal tumors.Type: ApplicationFiled: January 19, 2012Publication date: July 19, 2012Applicant: THE UAB RESEARCH FOUNDATIONInventors: Harald W. Sontheimer, Susan A. Lyons
-
Publication number: 20100215576Abstract: The present invention provides fusion proteins for the detection and treatment of neuroectodermal tumors. Previous work demonstrated that chlorotoxin is specific for glial-derived or meningioma-derived tumor cells. The current invention has extended the use of chlorotoxin-cytotoxin fusion proteins to treat the whole class neuroectodermal tumors such as gliomas, meningiomas, ependymonas, medulloblastomas, neuroblastomas, gangliomas, pheochromocytomas, melanomas, PPNET's, small cell carcinoma of the lung, Ewing's sarcoma, and metastatic tumors in the brain. Also, diagnostic methods are provided for screening neoplastic neuroectodermal tumors.Type: ApplicationFiled: February 16, 2010Publication date: August 26, 2010Applicant: The UAB Research FoundationInventors: Harald W. Sontheimer, Susan A. Lyons
-
Patent number: 7678759Abstract: The present invention provides fusion proteins for the detection and treatment of neuroectodermal tumors. Previous work demonstrated that chlorotoxin is specific for glial-derived or meningioma-derived tumor cells. The current invention has extended the use of chlorotoxin-cytotoxin fusion proteins to treat the whole class neuroectodermal tumors such as gliomas, meningiomas, ependymonas, medulloblastomas, neuroblastomas, gangliomas, pheochromocytomas, melanomas, PPNET's, small cell carcinoma of the lung, Ewing's sarcoma, and metastatic tumors in the brain. Also, diagnostic methods are provided for screening neoplastic neuroectodermal tumors.Type: GrantFiled: October 17, 2003Date of Patent: March 16, 2010Assignee: TransMolecular, Inc.Inventors: Harald W. Sontheimer, Susan A. Lyons
-
Patent number: 6870029Abstract: The present invention provides a recombinant toxin and monoclonal antibody which specifically binds to glial-derived or meningioma-derived tumor cells. Also provided are various methods of screening for malignant gliomas and meningiomas. Further provided are methods of treating malignant gliomas, including glioblastoma multiforme and astrocytomas.Type: GrantFiled: October 4, 2001Date of Patent: March 22, 2005Assignee: The UAB Research FoundationInventors: Harald W. Sontheimer, Nicole Ullrich
-
Publication number: 20040141981Abstract: The present invention provides fusion proteins for the detection and treatment of neuroectodermal tumors. Previous work demonstrated that chlorotoxin is specific for glial-derived or meningioma-derived tumor cells. The current invention has extended the use of chlorotoxin-cytotoxin fusion proteins to treat the whole class neuroectodermal tumors such as gliomas, meningiomas, ependymonas, medulloblastomas, neuroblastomas, gangliomas, pheochromocytomas, melanomas, PPNET's, small cell carcinoma of the lung, Ewing's sarcoma, and metastatic tumors in the brain. Also, diagnostic methods are provided for screening neoplastic neuroectodermal tumors.Type: ApplicationFiled: October 17, 2003Publication date: July 22, 2004Applicant: UAB Research FoundationInventors: Harald W. Sontheimer, Susan A. Lyons
-
Publication number: 20040081973Abstract: Described is the cloning and functional characterization of a novel splice variant of hSlo, the gene encoding the &agr;-subunit of IbTX sensitive human BK channels. The novel isoform of BK channels, which was termed gBK, contains a 63 amino acid insert at splice site 2, which differs by 33 amino acids from its nearest relative hbr5. gBK channels were over-expressed in glioma cells as evident from examination of human biopsy specimens. Moreover, gBK channel expression correlated positively with the relative degrees of malignancy of the tumor tissues. Heterologous expression of gBK in oocytes revealed that the pharmacological and biophysical properties of gBK are consistent with the properties of native BK currents in glioma cells. Furthermore, even when compared with its most homologous form hbr5, gBK showed distinct properties, including slowed channel activation and importantly, enhanced Ca2+ sensitivity at physiologically relevant [Ca2+]i values.Type: ApplicationFiled: February 27, 2003Publication date: April 29, 2004Inventors: Harald W. Sontheimer, Xiaojin Liu
-
Patent number: 6667156Abstract: The present invention provides fusion proteins for the detection and treatment of neuroectodermal tumors. Previous work demonstrated that chlorotoxin is specific for glial-derived or meningioma-derived tumor cells. The current invention has extended the use of chlorotoxin-cytotoxin fusion proteins to treat the whole class neuroectodermal tumors such as gliomas, meningiomas, ependymonas, medulloblastomas, neuroblastomas, gangliomas, pheochromocytomas, melanomas, PPNET's, small cell carcinoma of the lung, Ewing's sarcoma, and metastatic tumors in the brain. Also, diagnostic methods are provided for screening neoplastic neuroectodermal tumors.Type: GrantFiled: April 21, 1999Date of Patent: December 23, 2003Assignee: UAB Research FoundationInventors: Susan A. Lyons, Harald W. Sontheimer
-
Publication number: 20030021810Abstract: The present invention provides methods of treating individuals having a pathophysiological conditions that involve the activity of matrix metalloproteinase-2/pro-MMP2 system, comprising the step of: administering to said individual a pharmaceutical composition comprising a pharmaceutically effective dose of chlorotoxin and a pharmaceutically acceptable carrier.Type: ApplicationFiled: June 26, 2002Publication date: January 30, 2003Inventors: Harald W. Sontheimer, Craig C. Garner, Jessy Deshane
-
Publication number: 20020146749Abstract: The present invention provides fusion proteins for the detection and treatment of neuroectodermal tumors. Previous work demonstrated that chlorotoxin is specific for glial-derived or meningioma-derived tumor cells. The current invention has extended the use of chlorotoxin-cytotoxin fusion proteins to treat the whole class neuroectodermal tumors such as gliomas, meningiomas, ependymonas, medulloblastomas, neuroblastomas, gangliomas, pheochromocytomas, melanomas, PPNET's, small cell carcinoma of the lung, Ewing's sarcoma, and metastatic tumors in the brain. Also, diagnostic methods are provided for screening neoplastic neuroectodermal tumors.Type: ApplicationFiled: April 21, 1999Publication date: October 10, 2002Inventors: SUSAN A. LYONS PH.D., HARALD W. SONTHEIMER
-
Patent number: 6429187Abstract: The present invention provides a recombinant toxin and monoclonal antibody which specifically binds to glial-derived or meningioma-derived tumor cells. Also provided are various methods of screening for malignant gliomas and meningiomas. Further provided are methods of treating malignant gliomas, including glioblastoma multiforme and astrocytomas.Type: GrantFiled: November 28, 1997Date of Patent: August 6, 2002Assignee: UAB Research FoundationInventors: Harald W. Sontheimer, Nicole Ullrich
-
Publication number: 20020071841Abstract: The present invention provides a recombinant toxin and monoclonal antibody which specifically binds to glial-derived or meningioma-derived tumor cells. Also provided are various methods of screening for malignant gliomas and meningiomas. Further provided are methods of treating malignant gliomas, including glioblastoma multiforme and astrocytomas.Type: ApplicationFiled: November 28, 1997Publication date: June 13, 2002Inventors: HARALD W. SONTHEIMER, NICOLE ULLRICH
-
Publication number: 20020065216Abstract: The present invention provides a recombinant toxin and monoclonal antibody which specifically binds to glial-derived or meningioma-derived tumor cells. Also provided are various methods of screening for malignant gliomas and meningiomas. Further provided are methods of treating malignant gliomas, including glioblastoma multiforme and astrocytomas.Type: ApplicationFiled: October 4, 2001Publication date: May 30, 2002Applicant: The UAB Research FoundationInventors: Harald W. Sontheimer, Nicole Ullrich
-
Patent number: 6319891Abstract: The present invention provides a recombinant toxin and monoclonal antibody which specifically binds to glial-derived or meningioma-derived tumor cells. Also provided are various methods of screening for malignant gliomas and meningiomas. Further provided are methods of treating malignant gliomas, including glioblastoma multiforme and astrocytomas.Type: GrantFiled: November 28, 1997Date of Patent: November 20, 2001Inventors: Harald W. Sontheimer, Nicole Ullrich
-
Patent number: 6028174Abstract: The present invention provides a recombinant toxin and monoclonal antibody which specifically binds to glial-derived or meningioma-derived tumor cells. Also provided are various methods of screening for malignant gliomas and meningiomas. Further provided are methods of treating malignant gliomas, including glioblastoma multiforme and astrocytomas.Type: GrantFiled: November 28, 1997Date of Patent: February 22, 2000Assignee: UAB Research FoundationInventors: Nicole Ullrich, Harald W. Sontheimer
-
Patent number: 6013672Abstract: Astrocytes protect neurons from excitotoxic injury by maintaining low extra-cellular glutamate concentrations ([Glu].sub.o). Compromised astrocytic glutamate uptake has been implicated in acute and chronic neurological conditions, including Parkinson's disease. This invention provides evidence that [Glu].sub.o is modulated in a feed-back manner through activation of metabotropic glutamate receptors (mGluRs), particularly group II mGluRs. Furthermore, ACPD effects were mimicked by glutamate, suggesting that astrocytic glutamate transport is dynamically regulated with mGluRs acting as sensors for changes in [Glu]. Consequently, agonists of mGluR receptors are potent drugs to modulate extracellular glutamate levels in ways that are neuroprotective.Type: GrantFiled: December 18, 1997Date of Patent: January 11, 2000Assignee: UAB Research FoundationInventors: Zu-Cheng Ye, Harald W. Sontheimer
-
Patent number: 5905027Abstract: The present invention provides a recombinant toxin and monoclonal antibody which specifically binds to glial-derived or meningioma-derived tumor cells. Also provided are various methods of screening for malignant gliomas and meningiomas. Further provided are methods of treating malignant gliomas, including glioblastoma multiforme and astrocytomas.Type: GrantFiled: December 26, 1996Date of Patent: May 18, 1999Assignee: UAB Research FoundationInventors: Nicole Ullrich, Harald W. Sontheimer